Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analyses of lung adenocarcinoma cells and genome-wide maps of chromatin state in lung adenocarcinoma cells

ABSTRACT: Transcriptomic analyses of lung adenocarcinoma cells and genome-wide maps of chromatin state in lung adenocarcinoma cells

PROVIDER: PRJNA756032 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15514425_1.fastq.gz	Fastqsanger.gz
	SRR15514425_2.fastq.gz	Fastqsanger.gz
	SRR15514426_1.fastq.gz	Fastqsanger.gz
	SRR15514426_2.fastq.gz	Fastqsanger.gz
	SRR15514427_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Genome-wide maps of chromatin state in lung adenocarcinoma cells

Project description:Genome-wide maps of chromatin state in lung adenocarcinoma cells

| PRJNA756034 | ENA

Transcriptomic analyses of lung adenocarcinoma cells

Project description:Transcriptomic analyses of lung adenocarcinoma cells

| PRJNA843347 | ENA

Genome-wide maps of chromatin state in lung adenocarcinoma cells

Project description:We investigated the association between genetic variants in the histone modification regions and the prognosis of lung adenocarcinoma after curative surgery. Potentially functional SNPs were selected using integrated analysis of ChIP-seq and RNA-seq. The SNPs were analyzed in a discovery set (n=166) and a validation set (n=238). The associations of the SNPs with overall survival (OS) and disease-free survival (DFS) were analyzed. This study showed that genetic variants in the histone modification regions could predict the prognosis of lung adenocarcinoma after surgery.

2021-08-21 | GSE182384 | GEO

Ito2019 - gefitnib resistance of lung adenocarcinoma caused by MET amplification

Project description:The model is based on publication: Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification Abstract: Gefitinib, one of the tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR), is effective for treating lung adenocarcinoma harboring EGFR mutation; but later, most cases acquire a resistance to gefitinib. One of the mechanisms conferring gefitinib resistance to lung adenocarcinoma is the amplification of the MET gene, which is observed in 5–22% of gefitinib-resistant tumors. A previous study suggested that MET amplification could cause gefitinib resistance by driving ErbB3-dependent activation of the PI3K pathway. In this study, we built a mathematical model of gefitinib resistance caused by MET amplification using lung adenocarcinoma HCC827-GR (gefitinib resistant) cells. The molecular reactions involved in gefitinib resistance consisted of dimerization and phosphorylation of three molecules, EGFR, ErbB3, and MET were described by a series of ordinary differential equations. To perform a computer simulation, we quantified each molecule on the cell surface using flow cytometry and estimated unknown parameters by dimensional analysis. Our simulation showed that the number of active ErbB3 molecules is around a hundred-fold smaller than that of active MET molecules. Limited contribution of ErbB3 in gefitinib resistance by MET amplification is also demonstrated using HCC827-GR cells in culture experiments. Our mathematical model provides a quantitative understanding of the molecular reactions underlying drug resistance.

2024-09-02 | BIOMD0000000827 | BioModels

Transcriptomic analyses of lung adenocarcinoma cells

2021-08-21 | GSE182383 | GEO

MeRIP-sequencing in lung adenocarcinoma cells

Project description:MeRIP-sequencing in lung adenocarcinoma cells

| PRJNA719778 | ENA

LC/MS-based FFPE tissue-proteomic analyses of early lung adenocarcinoma

Project description:Clinical FFPE tissue proteomic analyses were performed for early lung adenocarcinomas including adenocarcinoma in-situ (AIS), minimally invasive adenocarcinoma (MIA) and lepidic predominant invasive adenocarcinoma (LPA).

2020-01-30 | PXD017334 | JPOST Repository

USP12-repressed genes in lung adenocarcinoma cells

Project description:USP12-repressed genes in lung adenocarcinoma cells

| PRJNA728108 | ENA

LC/MS-based FFPE tissue-proteomic analyses of Japanese lung adenocarcinoma

Project description:lung adenocarcinoma of 36 patients were subjected to LC/MS-based proteomic analyses. Triplicate runs for each sample were performed.

2019-10-17 | PXD015862 | JPOST Repository

Proteomic Identification of Lung Adenocarcinoma and Normal Lung Tissue

Project description:To identify proteomic of lung adenocarcinoma, we collected five pairs of lung adenocarcinoma and normal lung tissues from the clinic for analysis

2022-01-12 | PXD027008 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data